Press Release
CMS (867.HK/8A8.SG) Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer® and Cosmofer®
SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that, the Group through its wholly-owned subsidiary entered into an exclusive commercialization and supply agreement (the “Agreement”) with Pharmacosmos A/S for Iron Isomaltoside Injection (“Monofer®”) and Iron Dextran Injection (“Cosmofer®”) recently. In accordance with the Agreement, the Group has obtained an exclusive right to commercialize the products in the People’s Republic of China (for the purpose of this Agreement, excluding the Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan region). Pharmacosmos A/S will continue to manufacture and supply the products. The cooperation term shall be fifteen years from the effective date stipulated in the Agreement, which may be extended upon mutual agreement between the parties prior to expiry.
The two intravenous iron therapies under this cooperation are both originator products that have been approved for marketing in China and included in the China’s National Reimbursement Drug List (NRDL). Among them, Monofer® is an exclusive drug and the first third-generation intravenous iron therapy approved for marketing in China. It features an innovative and more stable matrix-like nanostructure and provides a superior safety profile[1]. Its single-dose full iron replenishment significantly reduces the number of infusions, enables faster improvement in hemoglobin levels and enhances clinical convenience. Another product, Cosmofer®, is currently the only intravenous iron therapy included in Category A of the NRDL and also the only one included in the National Essential Medicines List (NEML). With many years of accumulated clinical use, its efficacy and safety have been supported by accumulated clinical experience and published data.
The above two products will form a comprehensive intravenous iron product portfolio covering all channels and treatment scenarios, which can support meeting the clinical needs of different levels of healthcare institutions and different types of iron deficiency anemia (IDA) patients, providing more diversified, safe and effective treatment options for patients. Patients with iron deficiency (ID) and IDA are widely distributed across multiple clinical departments, including gastroenterology, cardiology, nephrology, obstetrics and gynecology, and orthopedics, which are all key specialty areas of the Group. The addition of the two products will generate efficient synergies with the Group’s existing marketed products in expert resources and academic promotion network, further strengthening the Group’s overall competitiveness in the field of anemia treatment, and is expected to have a positive impact on the Group’s performance.
More information about Monofer®
Monofer® was approved on 30 January 2021 for the treatment of iron deficiency in patients where oral iron preparations are ineffective, cannot be used, or where there is a clinical need for rapid iron supplementation. In 2023, Monofer® was included in the NRDL as a Category B reimbursable drug. Monofer® consists of nanoparticles with a stable, matrix-like structure composed of interchanging layers of iron atoms and short, linear isomaltose carbohydrates. This structure enables controlled iron release with low levels of labile iron, contributing to a favourable safety profile, including a low risk of hypersensitivity reactions and hypophosphatemia. Monofer® can be administered as a high-dose infusion of 1,000 mg or more in a single visit, whereas older therapies such as iron sucrose typically require repeated administrations of 100 to 200 mg. This enables full iron repletion in one treatment, reducing the need for multiple infusions, lowering the burden on patients and healthcare systems, and increasing infusion capacity. At the same time, the low risk of hypophosphatemia helps avoid complications such as fractures and supports recovery from fatigue, a key symptom of iron deficiency anaemia.
More information about Cosmofer®
Cosmofer® is a second-generation low-molecular-weight iron dextran injection. It was approved for marketing in Mainland China in 2003 and is indicated for patients with iron deficiency who cannot take oral iron preparations (such as those who are intolerant to oral iron or have unsatisfactory therapeutic outcomes). Cosmofer® also allows single-dose high-dose iron repletion. With many years of accumulated clinical use, its efficacy and safety have been supported by accumulated clinical experience and published data. Its dual status as a Category A NRDL-listed product and NEML supports its core role in iron supplementation in primary healthcare settings.
About Iron Deficiency and Iron Deficiency Anemia
ID and IDA are global health issues that commonly affect children, premenopausal women (particularly pregnant women) and the elderly. These conditions may impair the function of multiple organ systems, leading to a series of health problems such as growth retardation, behavioral disorders, cognitive impairment, reduced physical capacity, and peri-natal and peri-operative complications. They also significantly affect the prognosis of chronic diseases such as gastrointestinal diseases, chronic kidney disease, heart failure and tumors[2]. More than 1 billion people live with iron deficiency anaemia[3], making it one of the leading contributors to the global burden of disease[4]. Data from the Fourth National Nutrition Survey in China indicate that the prevalence of IDA among Chinese residents is 20.1%[5]. However, both patients and healthcare professionals have insufficient awareness of the disease. Less than 20% of patients with mild anemia receive diagnosis and treatment, while only about 50% of patients with severe anemia receive appropriate diagnosis and treatment[2]. This indicates significant underdiagnosis and undertreatment of ID/IDA. Iron supplementation is the standard treatment for ID/IDA and includes oral iron therapy and intravenous iron therapy. Intravenous iron therapy is an important option for patients who cannot tolerate oral iron, have inadequate response to oral therapy, require rapid iron repletion, or prefer full iron supplementation within one to two administrations[1,2,6]. However, due to insufficient awareness of IDA, patient adherence issues, hospitalization constraints, infusion convenience, and safety concerns regarding intravenous iron therapies, the clinical use of intravenous iron in China remains relatively conservative. A Chinese real-world study shows that the average total dose of iron sucrose used in IDA patients was approximately 511 mg, which was significantly lower than the target dose of 1,000 mg[2]. There is therefore a significant clinical need for intravenous iron therapies that offer high safety, strong demonstrated efficacy and single-dose full iron repletion. Monofer® and Cosmofer® together establish a comprehensive intravenous iron product portfolio covering multiple treatment scenarios, providing tiered treatment options for patients with iron deficiency anemia.
About Pharmacosmos A/S
Pharmacosmos A/S is a global leader in carbohydrate chemistry and innovative treatments for iron deficiency and iron deficiency anemia. Leveraging its deep expertise in carbohydrate chemistry and cell cycle biology, the company is committed to developing innovative therapies to address unmet patient needs, with a particular focus on iron metabolism and hematology-related diseases. Pharmacosmos A/S was founded in 1965 and is headquartered in Denmark, and employs more than 700 specialists from the United Kingdom, Ireland, the Nordic countries, Germany, the United States, Canada and China. With excellent product quality and strong clinical value, its core iron therapy products have been approved and widely used in multiple countries and regions worldwide, establishing strong technological capabilities and a solid market reputation.
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/gastroenterology/ophthalmology/skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.
Reference:
- Chinese Pharmacological Society Professional Committee of Drug‑induced Diseases, Guangdong Pharmaceutical Association. Expert consensus of clinical application and pharmaceutical care for intravenous iron agents (2024) [J]. Adverse Drug Reactions Journal, 2025, 27(3): 129-141. DOI: 10.3760/cma.j.cn114015⁃20240929⁃00070
- Liao Minjing, Zhang Liansheng. Standardized diagnosis and treatment of iron deficiency and iron‑deficiency anemia [J]. Chinese Journal of Internal Medicine, 2023, 62(6): 722-727. DOI: 10.3760/cma.j.cn112138-20230210-00074.
- Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME); 2020. Available from http://ghdx.healthdata.org/gbd-results-tool.
- Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2021 Jan 16;397(10270):233-248.
- Li Lijuan, Zhang Liansheng. Considerations on the standardized diagnosis and treatment of iron‑deficiency anemia [J]. National Medical Journal of China, 2021, 101(40): 3266-3270. DOI: 10.3760/cma.j.cn112137-20210609-01319.
- Red Blood Cell Disease (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association. Multidisciplinary expert consensus on the diagnosis, treatment and prevention of iron deficiency and iron deficiency anemia (2022 edition) [J]. National Medical Journal of China, 2022, 102(41): 3246-3256. DOI: 10.3760/cma. j.cn112137-20220621-01361.
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Brian Baldari on the Difference Between a Mentor and a Sponsor, and Why It Decides Promotions
-
ResilExec® Coaching founder Brian Baldari, Pharm.D., MBA, on why senior leaders who have plenty of advice and no advocacy stall at the same level for years.
BRICK, N.J., Oct 03, 2026, ZEX PR WIRE — Most senior professionals have someone they go to for advice. Far fewer have someone who argues for them in a room they are not in. According to Brian Baldari, Pharm.D., MBA, founder of ResilExec® Coaching, that distinction accounts for a large share of stalled advancement among otherwise strong performers.
Baldari spent 24 years inside pharmaceutical, healthcare, and enterprise leadership organizations. He held five successive Director-level roles, moved from Director to Vice President and Senior General Manager in 18 months, and led the commercial launch of 14 brands. He now works with Associate Directors, Directors, Senior Directors, Executive Directors, and Vice Presidents inside pharmaceutical, healthcare, and enterprise IT organizations.
“A mentor talks to you. A sponsor talks about you,” Baldari says. “One of those changes your calendar. The other changes your title.”
Advice Is Not Advocacy
Mentorship is widely available and widely encouraged. Many organizations run formal programs for it. A mentor offers perspective, context, and guidance, and that guidance has real value early in a career when the primary gap is knowledge.
Sponsorship operates differently. A sponsor spends their own credibility on someone else. They put a name forward on a succession slate, defend a candidate during calibration, and accept the consequences if the bet does not pay off. That is a materially different act, and it is not something an organization can mandate.
“Leaders collect mentors because mentors are easy to ask for,” Baldari says. “Nobody feels awkward requesting advice. Asking someone to spend their reputation on you is a different conversation, and most people never have it.”
Where the Gap Shows Up
The gap becomes visible at the point where advancement decisions are made collectively. Calibration sessions and succession discussions involve people across multiple functions, many of whom have no direct experience of a given candidate’s work. In those rooms, a candidate is represented by whoever chooses to speak.
“If nobody in that room can describe what you do at enterprise scale, you are not in the conversation, regardless of your review,” Baldari says. “The decision is not made on the strength of your record. It is made on the strength of the description someone else gives of it.”
Baldari notes that this is where strong performers are most often surprised. Their performance ratings are high, their manager is supportive, and the outcome still does not change, because the people who influenced the decision were never engaged.
Sponsorship as a Variable
Sponsorship is one of five variables in Baldari’s Promotion Math
framework, alongside Performance, Visibility, Narrative, and Timing. In his assessment, strong performers optimize the first variable and leave the remaining four unattended, then attribute the result to politics.
“Performance gets you noticed. Positioning gets you promoted,” Baldari says. “Sponsorship is the variable people find hardest to work on, because it requires asking for something rather than producing something.”
What Changes the Outcome
Baldari advises leaders to identify the specific individuals who will participate in the decisions that affect them, then assess honestly whether those individuals could describe their contribution without prompting. In most cases the answer is no, and that is the actionable finding.
From there the work is practical rather than social. It involves delivering value to those individuals rather than checking in with them, framing results at enterprise level rather than functional level, and showing up in forums where that work is visible to people beyond a direct reporting line.
“You do not recruit a sponsor by asking them to be one,” Baldari says. “You give them something worth putting their name next to, and you make sure they understand what it was.”
About Brian Baldari
Brian Baldari, Pharm.D., MBA, based in Brick, New Jersey, is the founder of ResilExec® Coaching and Resilient Performance Group LLC. He spent 24 years inside pharmaceutical, healthcare, and enterprise leadership organizations, held five successive Director-level roles, and advanced from Director to Vice President and Senior General Manager in 18 months. He led the commercial launch of 14 brands across rare and chronic disease categories, led an organization of more than 250 people, and has mentored more than 50 leaders across three continents. Through ResilExec Coaching, he helps Associate Directors, Directors, Senior Directors, Executive Directors, and Vice Presidents accelerate career growth through personalized executive coaching, leadership development, and strategic career positioning.
Media Contact
Resilient Performance Group LLC
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Timothy Caraboolad Publishes a Buyer’s Checklist for New-Build Condos in South Florida
-
Real estate developer Timothy Caraboolad is releasing a set of questions first-time buyers should ask before putting money down on a new-build apartment in South Florida.
A market full of new buildings, and a lot of first-time buyers
Florida, USA, Oct 03, 2026, ZEX PR WIRE — South Florida has no shortage of new construction. Buildings go up fast, sales offices open before the concrete cures, and renderings promise more than any buyer can verify in a single walkthrough.
Timothy Caraboolad, a real estate developer and designer based in Palm Beach, Florida, has spent years on the other side of that process, building high-end custom homes through his firm Lad Design. He says the buyers who end up happiest are the ones who ask harder questions earlier, not the ones who fall for the best rendering.
“A sales gallery is designed to sell you a feeling,” he says. “Your job as a buyer is to slow that down and ask what you’re actually getting for the price.”
What to check before signing anything
Caraboolad points first-time buyers toward a few areas that matter more than finishes.
Construction quality behind the walls. Countertops and cabinetry are easy to judge. What is inside the walls is not. Caraboolad suggests asking who the general contractor is, how long they have built in the area, and whether the building uses concrete or wood-frame construction, since that affects sound, insurance, and long-term durability in a hurricane-prone region.
HOA fees and what they actually cover. New buildings often advertise low fees at launch that rise once amenities open and reserves get funded. “Ask for the projected budget once the building is fully occupied, not just the introductory number,” Caraboolad says. He recommends buyers ask specifically what percentage of the fee goes into reserves, since that determines whether the building can pay for a roof or a seawall repair without a special assessment.
Storm readiness. In South Florida, this is not optional. Buyers should ask about impact windows, generator backup for elevators and common areas, and flood elevation. Caraboolad says a building’s flood zone designation should be requested in writing, not estimated by a sales agent.
Parking and storage, spelled out. Some buildings sell parking as a deeded asset. Others assign it and can reassign it later. Caraboolad says this distinction matters more than most buyers realize until after closing.
Developer track record. A new building has no resale history to check. Caraboolad suggests buyers look at other projects the same developer has completed, not just renderings of the one being sold, and ask how those buildings have held up.
Timing the purchase
For pre-construction units, Caraboolad says the biggest risk is not price, it is timeline. Delays are common, and buyers should understand what happens to their deposit if the closing date slips.
“Get the outside date for completion in writing,” he says. “And ask what your options are if that date passes.”
He also encourages buyers to walk a finished unit in the same building, or a comparable one from the same developer, before relying on a model unit that may use upgraded finishes not included in the base price.
Why this matters for first-time buyers specifically
Caraboolad says first-time buyers face a particular disadvantage: they often do not know which questions are normal to ask, so they accept vague answers.
“An experienced buyer will push back on a soft answer about HOA reserves or insurance history,” he says. “A first-time buyer might just assume that’s how it works. It isn’t. You’re allowed to ask for documentation before you commit.”
His broader point is that a new building can be a strong investment in South Florida, but only when the buyer treats the sales process the same way a developer would: checking budgets, checking materials, and checking the people building it, before checking the view.
About Timothy Caraboolad
Timothy Caraboolad is an entrepreneur, real estate developer, and designer based in Palm Beach, Florida. He is the founder of Lad Design, a South Florida firm building high-end custom homes, and previously founded Arc Design, a luxury residential development and design firm in the Boston area. He holds a Bachelor’s Degree in International Business from Rollins College.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Jermaine Gassaway: A checklist for parents choosing school leadership
-
Jermaine Gassaway, a superintendent and public education advocate, outlines what parents should look for in school and district leaders before enrolling their children.
Why leadership is the first thing to check
North Carolina, USA, Oct 03, 2026, ZEX PR WIRE — Parents often start a school search by looking at test scores or building tours. Jermaine Gassaway says that misses the bigger question: who is running the school, and how do they lead.
“A building can look great and still have weak instruction,” Gassaway says. “The leader sets the tone for everything else. If you skip that part of the search, you’re missing the most important piece.”
Gassaway has worked as a teacher, a principal, and a superintendent. That range gives him a view of leadership from more than one seat, and he says the questions parents ask should change depending on what they can actually observe.
What to ask before you tour the building
Gassaway suggests parents start with a short list of questions for any principal or superintendent they meet.
How do you measure growth, not just scores. A single test score tells a parent almost nothing about whether their child is improving. Gassaway says leaders who can talk about growth over time, not just a snapshot, are paying attention to the right thing.
How often are you in classrooms. A principal’s visibility in classrooms is a signal of how closely they track teaching day to day. Gassaway says parents should ask directly how often the leader observes instruction and gives feedback to teachers.
What happens when a student falls behind. Every school has students who struggle. Gassaway says the real question is whether there is a clear plan, with specific support, for those students, or whether it is left to chance.
How do you support new teachers. Turnover affects children directly. Gassaway says parents should ask how new teachers are coached in their first year, since that shapes whether a child gets a stable classroom experience.
Red flags parents should not ignore
Gassaway points to a few signs that should raise questions, even if the rest of a school visit goes well.
A leader who cannot describe how they use data. If a principal talks only in generalities about student progress, Gassaway says that is worth a follow-up question.
A staff that seems unsettled or unclear on expectations. Gassaway says parents can pick up on this just from talking to teachers or reading how a school communicates with families.
No clear answer on discipline or support plans. Parents should expect a straight answer on how the school handles behavior and academic struggles, not a vague reassurance.
What good leadership sounds like
Gassaway says strong school leaders tend to talk in specifics. They can describe how a reading program works, not just that the school “cares about literacy.” They know their staff by name and can speak to strengths and gaps on their team. They treat parent questions as normal, not as a challenge to be managed.
“You can tell a lot from how a leader answers a hard question,” Gassaway says. “Do they get defensive, or do they give you a real answer. That tells you how they’ll treat you once your child is enrolled.”
A short list parents can bring to a school visit
Gassaway recommends parents keep it simple: three or four questions, asked directly, with room to follow up.
-
How do you track whether students are growing, not just passing.
-
How often are you in classrooms, and what do you look for.
-
What is your plan when a student is behind grade level.
-
How do you support teachers who are new to the school.
He says the answers matter less for their polish and more for their specificity. “A leader who knows their school will have real answers,” Gassaway says. “A leader who doesn’t will talk around it.”
About Jermaine Gassaway
Jermaine Gassaway is a superintendent based in Charlotte, North Carolina. He is a former teacher and school principal, and the author of “Unopened Books: Multiplying the 2%” and “When You Arrive: A Children’s Book About Racism.” He is a graduate of Johnson C. Smith University and has worked in public education for more than a decade.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
-
Press Release1 week ago
Just Keepers Spotlights Keeper iD’s New Range of Junior Goalie Gloves
-
Press Release1 week ago
Results Digital Expands Website Design Offerings for General Contractors in Houston TX
-
Press Release6 days ago
New Experiences in Shanghai for Mid-Autumn Festival and National Day! The 2026 International Audio-Visual Arts Carnival Unveils a “Technology + Culture” Audio-Visual Feast
-
Press Release7 days ago
Piya Saliba Releases Free Community Connection Checklist to Help People Build Stronger Relationships
-
Press Release1 week ago
Whimsical Halloween Wardrobe Ready: Arshiner Kids’ Outfits Light Up the Trick-or-Treat Adventure
-
Press Release1 week ago
Painted Brick Digital Named Among Expertise.com’s Top 8 Legal Marketing Companies in Scottsdale
-
Press Release7 days ago
Gary Bassett Shares Lessons From 45 Years Across Finance and Technology
-
Press Release7 days ago
Nivia Fontanez Highlights the Often-Overlooked Role of Radiology Technologists in Patient Care
